The Plasma Lipoproteins

Kannel WB , Castelli WP , Gordon T. , McNamara P. : Serum cholesterol, lipoproteins, and the risk of coronary heart disease. Ann Intern Med 74:1-12, 1971.

Goldstein JL , Brown MS : The LDL receptor defect in familial hypercholesterolemia. Implications for pathogenesis and therapy. Med Clin N Am 66:335-362, 1982.

Heiss G. , Johnson NJ , Reiland S. , et al: The epidemiology of plasma high density lipoprotein levels (summary). The Lipid Research Clinics Program Prevalence Study. Circ 62(Suppl IV):116-136, 1980.

Grundy SM : Dietary fats and sterols. In: Nutrition, Lipids, and Coronary Heart Disease, ed. by Levy RI , Rifkind BM , Dennis BH , Ernst ND. New York, Raven Press, 1979, pp. 89-118.

Stamler J. : Population studies. In: Nutrition, Lipids, and Coronary Heart Disease, ed. by Levy RI , Rifkind BM , Dennis BH , Ernst ND. New York, Raven Press, 1979, pp. 25-88.

Criqui MH , Wallace RB , Heiss G. , et al: Cigarette smoking and plasma high-density lipoprotein cholesterol. The Lipid Research Clinics Program Prevalence Study. Circ 62(Suppl IV):70-76, 1980.

Glueck CJ , Tayior HL , Jacobs D. , et al: Plasma high-density lipoprotein cholesterol: Association with measurements of body mass. The Lipid Research Clinics Program Prevalence Study . Circ 62(Suppl IV):62-69, 1980.

Haskell WL , Taylor HL , Wood PD , et al: Strenuous physical activity, treadmill exercise test performance and high-density lipoprotein cholesterol. The Lipid Research Clinics Program Prevalence Study. Circ 62(Suppl IV):53-61, 1980.

Ernst N. , Fisher M. , Smith W. , et al: The association of plasma high-density lipoprotein cholesterol with dietary intake and alcohol consumption. The Lipid Research Clinics Program Prevalence Study. Circ 62(Suppl IV):41-52, 1980.

Wallace RB , Hoover J. , Barrett-Connor E. , et al: Altered plasma lipid and lipoprotein levels associated with oral contraceptive and oestrogen use. Lancet 2:111-114, 1979.

Beaglehole R. , Trost DC , Tamir I. , et al: Plasma high-density lipoprotein cholesterol in children and young adults. The Lipid Research Clinics Program Prevalence Study Circ 62(Suppl IV):83-92, 1980.

Cornfield J. , Mitchell S. : Selected risk factors in coronary disease. Possible intervention effects. Arch Environ Health 19:382-394, 1969.

National Diet-Heart Study Research Group. The National Diet-Heart Study Final Report Circ 37(Suppl I): 1-419, 1968.

The Lipid Research Clinics Program. The Coronary Primary Prevention Trial: Design and implementation. J Chron Dis 32:609-631, 1979.

The Coronary Drug Project. Findings leading to discontinuation of the 2.5 mg/day estrogen group. JAMA 226:652-657, 1973.

The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231:360-381, 1975.

Rifkind BM , Gordon DJ : Bile acid sequestrant resins in the treatment of hyperlipoproteinemia. In: Hypolipidemic Drugs: Therapeutic Selectivity and Risk/Benefit Assessment , ed. by Paoletti R , et al. New York, Raven Press, 1982, pp. 287-290.